Omeros (NASDAQ: [[ticker:OMER]]), the Seattle-based biotech company, has struck a deal in which it may raise as much as $40 million over the next two years through selling shares of common stock to a single investor, Azimuth Opportunity. Omeros raised $68.2 million through its initial public offering in October, but securing more money at certain times should help strengthen its bargaining position “as we pursue strategic opportunities,” the company said in a statement.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
